The global idiopathic pulmonary fibrosis market is estimated to grow over the forecast period due to increased adoption of inorganic growth strategies such as collaboration by leading industry players. For example, in January 2022, Benevolent AI, a clinical-stage AI (Artificial Intelligence) drug discovery startup, expanded its AI-powered drug discovery relationship with AstraZeneca, a pharmaceutical business.
The three-year expansion includes an initial payment, research funding, development milestone payments, and an agreement on future revenues. This partnership is anticipated to expand ongoing research efforts to find various novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) in the future. As the number of idiopathic pulmonary fibrosis (IPF) cases increases, so does the demand for appropriate therapeutic strategies.
The devastating nature of IPF needs management measures that improve patient quality of life, creating market demand for novel therapeutic alternatives. This demographic transition highlights the critical need to expand healthcare facilities and combat the disease's rising occurrence.
Growing emphasis on the research and development activities in the idiopathic pulmonary fibrosis market by the leading key players is expected to propel the growth of the market. Furthermore, growing adoption of advanced technologies such as artificial intelligence platform, and rising emerging strategies such as research and development activities and others in the markets can provide desirable opportunities for growth in the idiopathic pulmonary fibrosis market.
For example, in June 2021, Sunshine Lake Pharma Co., Ltd., a manufacturing company, announced that the clinical trial to evaluate the efficacy and safety of different doses of HEC585 Tablets with Pirfenidone in the treatment of idiopathic pulmonary fibrosis was started. This clinical trial is ongoing in phase 2.
Similarly, in October 2024, The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced the first dose of a pioneering regenerative lung therapy, CMR316, has been given in a phase 1 trial assessing safety and tolerability in healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF). This once-weekly, inhaled drug has potential to revolutionize treatment of lung diseases by stimulating stem cells to regenerate damaged lung tissue.
Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition wherein lungs develop stiff and thick tissues. This condition leads to scarring of the tissues, that causes breathing problems, and further fails in delivering sufficient amount of oxygen to the organs. It is a progressive condition and can lead to permanent damage to the lungs.
The precise etiology of idiopathic pulmonary fibrosis is not clear, yet certain factors could induce acute exacerbation of the condition. For instance, based on American Lung Association statistics, close to 50,000 new cases of idiopathic pulmonary fibrosis are reported every year. The increased awareness regarding idiopathic pulmonary fibrosis among patients and medical experts has accelerated the demand for treatment drugs and diagnosis processes to alleviate the increasing risk of disease.
At present, a number of pharma firms and drug developers are spending time and effort on the creation of drugs to meet the unmet treatment need in IPF patients. In point of fact, recently in October 2023, Bristol Myers Squibb reported receiving US FDA Breakthrough Therapy Designation for its investigational LAP1 Antagonist to treat progressive pulmonary fibrosis diseases in patients.
Based on the drug type, the idiopathic pulmonary fibrosis market is bifurcated into nintedanib, pirfenidone, and other drug types. However, in addition to Ofev a number of nintedanib generic drugs are also available in the market. The second branded drug Esbriet (pirfenidone) from Roche, the company recorded dropping sales due to generic competition. With the rising cases of idiopathic pulmonary fibrosis (IPF), the demand for proper therapeutic intervention also rises.
The catastrophic character of IPF requires management strategies that enhance the quality of life in patients, making market demand for new therapeutic options more relevant. This demographic change underscores the urgent need to increase healthcare facilities and fight the increasing incidence of the disease.
With the growing number of idiopathic pulmonary fibrosis (IPF) cases comes the increased need for viable therapeutic strategies. The destructive nature of IPF requires measures to manage it and enhance the quality of life for patients, thus building market demand for new therapeutic options. The demographic shift underscores the importance of the expansion of healthcare units and the fight against the increasing prevalence of the disease.
North America's idiopathic pulmonary fibrosis therapy market dominated the global market in 2024, accounting for 38.2% of total revenue. The region has a well-developed healthcare infrastructure, appropriately equipped facilities, and expert IPF diagnosis and management abilities, allowing for timely and efficient treatment.
Furthermore, substantial research and development operations, accompanied by advantageous reimbursement regulations, improve access to approved medications such as pirfenidone and nintedanib.
In 2024, the therapy market for idiopathic pulmonary fibrosis in the United States dominated North America in terms of revenue share. The country is supported by a solid healthcare system, which allows for timely diagnosis and effective treatment. Pirfenidone and nintedanib have received expedited approvals, increasing patient access, and consistent R&D activities in the United States ensure innovative treatment strategies.
The major players operating in the global market are focusing on advancements in research and development to meet the rising demand for idiopathic pulmonary fibrosis treatment. Moreover, manufacturers are entering into partnerships for the development of innovative products.
Key players operating in the global Idiopathic Pulmonary Fibrosis Drugs market include:
NA
NA
NA
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Idiopathic Pulmonary Fibrosis Drugs Market
